Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Immune surveillance should be directed to suppress tumor development and progression, involving a balance of coinhibitory and costimulatory signals that amplify immune response without overwhelming the host. Immunotherapy confers durable clinical benefit in 'immunogenic tumors', whereas in other tumors the responses are modest. Thus, immune checkpo...
Alternative Titles
Full title
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5705793
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5705793
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt-2016-0014
